Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12046033 | 0.96 | P2RX3 (0.80) | P2RX3 | |
| SCHEMBL12045898 | 0.96 | P2RX3 (0.80) | P2RX3 | |
| SCHEMBL12046070 | 0.95 | P2RX3 (0.82) | P2RX3 | |
| SCHEMBL12046040 | 0.94 | P2RX3 (0.79) | P2RX3 | |
| SCHEMBL12046047 | 0.94 | P2RX3 (0.79) | P2RX3 | |
| SCHEMBL12046057 | 0.93 | P2RX3 (0.75) | P2RX3 | |
| SCHEMBL12046216 | 0.91 | P2RX3 (0.75) | P2RX3 | |
| SCHEMBL12046103 | 0.91 | P2RX3 (0.75) | P2RX3 | |
| SCHEMBL12046098 | 0.90 | P2RX3 (0.72) | P2RX3 | |
| SCHEMBL12045973 | 0.90 | P2RX3 (0.72) | P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718790-B2 | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718790-B2 | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9688643-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-9688643-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-20160185736-A1 | NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. | 2016-06-30 | — | — | US | disclosed |
| US-20160185736-A1 | NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. | 2016-06-30 | — | — | US | disclosed |
| US-9150546-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150546-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185736-A1 | NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX5, P2RX2 | P2RX3 1/4885 |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX5, P2RX2 | P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.